The change in left ventricular (LV) ejection fraction at 12 months was significantly greater in the patients taking deferiprone rather than deferoxamine. In this analysis, 29 deferiprone-treated patients and 31 deferoxamine-treated patients are included (1 deferoxamine-treated patient was excluded because T2^* and ejection fraction were not measured at 6 and 12 months, and the 4 dropouts were included using last observation carried over). Standard error bars are shown.